Filing Details

Accession Number:
0001209191-18-040520
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-07-02 20:20:19
Reporting Period:
2018-06-28
Accepted Time:
2018-07-02 20:20:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1340652 Chemocentryx Inc. CCXI Pharmaceutical Preparations (2834) 943254365
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1423084 J. Thomas Schall C/O Chemocentryx, Inc.
850 Maude Avenue
Mountain View CA 94043
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-06-28 10,757 $6.00 2,195,751 No 4 M Direct
Common Stock Disposition 2018-06-28 10,757 $14.00 2,184,994 No 4 S Direct
Common Stock Acquisiton 2018-06-29 100 $6.00 2,185,094 No 4 M Direct
Common Stock Disposition 2018-06-29 100 $14.10 2,184,994 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2018-06-28 10,757 $0.00 10,757 $6.00
Common Stock Stock Option (right to buy) Disposition 2018-06-29 100 $0.00 100 $6.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
224,243 2009-07-29 2019-07-29 No 4 M Direct
224,143 2009-07-29 2019-07-29 No 4 M Direct
Footnotes
  1. Shares sold are associated with stock options that will expire in July 2019.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  3. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $14.00 to $14.01 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  4. As of June 28, 2018, and prior to this transaction, the exercised options were fully vested.
  5. Not applicable.